Are COVID-19 Vaccines Safe?

Vaccine safety is a top priority for health regulators everywhere and COVID-19 vaccines were no exception. Before any vaccine is approved for use in the UK, it has to pass through several phases of clinical trials involving thousands of volunteers, assessing both how well it works and how safe it is.

How the vaccines were tested and approved

In the UK, vaccines are approved by the Medicines and Healthcare products Regulatory Agency (MHRA), an independent regulator. Approval requires evidence from large-scale clinical trials showing the vaccine is both effective and meets strict safety standards. Because COVID-19 vaccines were developed during a global public health emergency, trial phases that would normally run one after another were run in parallel where it was safe to do so and manufacturing began before approval was granted so that doses would be ready sooner. None of the standard safety checks were skipped.

Which vaccines have been used in the UK

The main vaccines rolled out in the UK included the Pfizer-BioNTech and Moderna mRNA vaccines and the Oxford-AstraZeneca viral vector vaccine. Each uses a different method to teach the immune system to recognise the coronavirus spike protein, but all were required to clear the same regulatory bar for safety and effectiveness before being approved.

Common side effects

Most side effects from COVID-19 vaccines are mild and short-lived, typically resolving within a day or two. These commonly include:

• Soreness, redness or swelling at the injection site
• Tiredness or headache
• Muscle aches or chills
• A mild, short-lived fever

These reactions are a normal sign that your immune system is responding to the vaccine, not a sign that something has gone wrong.

Rare risks and ongoing monitoring

Serious side effects are uncommon. A small number of rare but recognised risks have been identified over time, such as a link between the AstraZeneca vaccine and a very rare blood clotting condition in a small number of recipients and a rare risk of myocarditis (inflammation of the heart muscle) linked to mRNA vaccines, mostly in younger men and usually mild and short-lived. These risks were identified precisely because vaccine safety continues to be monitored closely after approval, not despite it.

In the UK, this ongoing monitoring happens through the MHRA's Yellow Card scheme, which collects reports of suspected side effects from the public and healthcare professionals. Similar systems operate in other countries and international data is compared to spot any patterns quickly. When new risks are identified, health authorities adjust guidance accordingly, for example by recommending certain vaccines for some age groups rather than others.

Weighing risk against benefit

For the vast majority of people, the risk of serious illness from COVID-19 itself is substantially higher than the risk of a serious vaccine side effect. This is why vaccination has continued to be recommended, particularly for older adults and people with health conditions that put them at greater risk from the virus.

Where to find reliable information

Vaccine advice can change as new evidence emerges, so it's worth checking current guidance directly from the NHS or your GP rather than relying on older articles or social media. If you have specific health conditions or concerns, a conversation with your doctor or pharmacist is the best way to get advice tailored to your situation.

How clinical trials are structured

Vaccine trials typically progress through several phases. Phase 1 trials involve a small number of volunteers and focus mainly on safety and dosage. Phase 2 trials expand to a larger group, gathering more safety data and early evidence of effectiveness. Phase 3 trials involve thousands of participants, often across multiple countries, comparing outcomes between people who received the vaccine and those who received a placebo, to establish how well it actually works in the real world.

Only after successfully completing these phases, with the data reviewed by an independent regulator such as the MHRA, can a vaccine be approved for public use. Phase 4 monitoring then continues indefinitely once a vaccine is in use, tracking real-world safety across millions of people.

Mixing vaccine types

Because supply and availability varied over the course of the rollout, some people received a first and second dose from different vaccine manufacturers, an approach known as a mixed or heterologous schedule. Studies generally found mixed schedules to be safe and, in some cases, to produce a strong immune response, though guidance on whether mixing is recommended has varied by country and by vaccine type.

Frequently asked questions

Do vaccines contain live virus?

No. None of the main COVID-19 vaccines used in the UK contain a live version of SARS-CoV-2, so they cannot give you COVID-19. They work by teaching your immune system to recognise the spike protein, either using a harmless viral vector or mRNA instructions.

Can you catch COVID-19 after being vaccinated?

Yes, vaccination significantly reduces the risk of severe illness, hospitalisation and death, but it doesn't guarantee you won't catch the virus at all, particularly against newer variants. This is normal for many vaccines and doesn't mean the vaccine has failed.

Are booster doses still recommended?

Booster programmes continue to be offered to eligible groups, typically ahead of winter, though eligibility criteria change over time. Current NHS guidance is the best source for whether you're eligible.

Vaccine safety monitoring systems around the world

The UK's Yellow Card scheme isn't unique. Most countries with established healthcare systems run comparable pharmacovigilance programmes designed to track vaccine safety after approval. In the United States, this includes the Vaccine Adverse Event Reporting System (VAERS), while the European Medicines Agency coordinates safety monitoring across the European Union. The World Health Organization also compiles international safety data to help identify patterns that might not be visible from any single country's figures alone.

These systems work by collecting reports of health events that occur after vaccination, which are then reviewed by scientists and statisticians to determine whether there's a genuine causal link to the vaccine or whether the event would likely have happened anyway, since illness and injury occur in the population regardless of vaccination. This is an important distinction: a report of an adverse event doesn't automatically mean the vaccine caused it and the review process exists specifically to work out which events are genuinely linked.

Because so many countries run parallel monitoring systems and regularly share findings, it's very difficult for a genuine, significant safety signal to go unnoticed. This international, overlapping approach to monitoring is one of the main reasons regulators have consistently maintained confidence in the safety of approved COVID-19 vaccines.

Vaccination during pregnancy

Pregnant women face a higher risk of severe complications from COVID-19, which is why vaccination has generally been recommended for pregnant women in the UK and many other countries. Large studies conducted since the vaccines were rolled out have not identified safety concerns specific to pregnancy and health authorities including the NHS have continued to recommend vaccination at any stage of pregnancy for those who are eligible. Anyone with specific questions about vaccination during pregnancy should speak with their midwife or GP, who can offer advice tailored to their individual circumstances.

Vaccinating children

COVID-19 vaccination has also been offered to children and teenagers in various countries, including the UK, generally at a lower dose than the adult vaccine and typically focused on children with underlying health conditions that put them at higher risk, rather than being offered universally to all children. This reflects the fact that severe illness from COVID-19 is considerably rarer in children than in adults, so the balance of risk and benefit for routine vaccination differs by age group. Parents with questions about whether vaccination is recommended for their child can check current NHS guidance or speak to their GP.